Phase I safety and pharmacokinetic (PK) study of SU014813 (S) in combination with docetaxel (D) in patients (pts) with solid tumors (STs)

被引：0
|
作者：
Schoffski, P.
机构：
[1] Univ Ziekenhuizen Leuven, Louvain, Belgium
[2] Erasmus MC, Rotterdam, Netherlands
[3] Pfizer SRL, Milan, Italy
[4] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3554
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
    de Jonge, M. J. A.
    Dumez, H.
    Kitzen, J. J. E. M.
    Beuselinck, B.
    Verweij, J.
    Courtney, R.
    Battista, A.
    Brega, N.
    Schoffski, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (09) : 1328 - 1335
  • [2] Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
    Fiedler, W. M.
    Giaccone, G.
    Lasch, P.
    Van der Horst, I.
    Brega, N. M.
    Raber, S.
    Shalinsky, D.
    Ljubmir, V.
    Bokemeyer, C.
    Boven, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs)
    Hamberg, P.
    Steeghs, N.
    Loos, W. J.
    van der Biessen, D. J.
    den Hollander, M. A.
    Tascilar, M.
    Verweij, J.
    Gelderblom, H.
    Sleijfer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.
    Puglisi, M.
    van Doorn, L.
    Blanco-Codesido, M.
    De Jonge, M. J.
    Moran, K.
    Yang, J.
    Busman, T.
    Franklin, C.
    Mabry, M.
    Krivoshik, A.
    Humerickhouse, R.
    Molife, L. R.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    VerMeulen, W.
    Harper, K.
    Liu, G.
    Tye, L.
    Chao, R.
    Traynor, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Traynor, A. M.
    Sandler, A. B.
    Schiller, J. H.
    Ilagan, J.
    Vermeulen, W. L.
    Liu, G.
    Tye, L.
    Verkh, L.
    Chao, R.
    Robert, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors
    Hamberg, P.
    Mathijssen, R. H.
    de Bruijn, P.
    van der Biessen, D.
    Loos, W. J.
    Sleijfer, S.
    Verweij, J.
    de Jonge, M. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 177 - 177
  • [8] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study
    Traynor, A.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    VerMeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Robert, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110
  • [9] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
    Izquierdo, MA
    Pontón, JL
    García, M
    Navarro, M
    Mesia, R
    Cardenal, F
    Gil, M
    Germá, JR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [10] Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
    Hamberg, Paul
    Boers-Sonderen, Marye
    Loos, Walter J.
    De Jonge, Maja J.
    Van der Graaf, Winette T. A.
    Suttle, Ben B.
    Eskens, Ferry
    Verweij, Jaap
    Van Herpen, Carla
    Sleijfer, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345